Company intelligence / Profile preview

China Reform Overseas

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

CRHC manages over 700 billion yuan in assets (as of 2019). Involved in major deals including stakes in China Tower, Syngenta acquisition consortium, and SOE investments in strategic industries. In 2022, its private equity arm was ranked largest in Asia-Pacific by fundraising. Planning a $14B fund for emerging industries as of 2023.

Industry: Investors

Partnerships

Shanghai Stock ExchangeMinistry of Industry and Information TechnologyPostal Savings Bank of ChinaChina Construction Bank

Beyond the preview

Go deeper on China Reform Overseas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Reform Overseas.

Explore the full profile